Recombinant Human IL-2 Protein

Beta LifeScience SKU/CAT #: BL-1714NP
BL-1714NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-1714NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human IL-2 Protein

Beta LifeScience SKU/CAT #: BL-1714NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Interleukin-2 is produced by our E.coli expression system and the target gene encoding Ala21-Thr153 is expressed.
Accession P60568
Synonym Interleukin-2; IL-2; T-Cell Growth Factor; TCGF; Aldesleukin; IL2
Gene Background Interleukin-2(IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system,belongs to the IL-2 family. It is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions that are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine-activated killer cells, monocytes, macrophages and oligodendrocytes.
Molecular Mass 15.5 KDa
Apmol Mass 14 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 10mM sodium citrate, pH 4.0.
Endotoxin Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Biologically active. Please contact us to obtain bioactivity data.
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells.
Subcellular Location Secreted.
Protein Families IL-2 family
Database References
Associated Diseases A chromosomal aberration involving IL2 is found in a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(4;16)(q26;p13) with involves TNFRSF17.

Gene Functions References

  1. the co-culture with human T lymphocytes induce the in vitro maturation of human intestinal organoids, and identify STAT3-activating interleukin-2 (IL-2) as the major factor inducing maturation. PMID: 30072687
  2. This study emphasized on the bone marrow and blood plasma levels of IL-2 in aplastic anaemia and their relationship with disease severity. The results indicate towards the fact that IL-2 may have an important association with the marrow failure of AAA patients and thus can help in disease development. Further study is necessary for better understanding. PMID: 30139310
  3. The present study demonstrated no association between IL-2 (T-330G), IL-16 (T-295C), and IL-17 (A-7383G) genotypes and CP in an Iranian population. PMID: 29400002
  4. In contrast with some reports involving the correlation between polymorphisms of the TGF-beta1 and IL-2 genes and inhibitor development in the world, no statistically significant differences in analysis of the alleles and genotypes for TGF-beta and IL-2 genes were found between the inhibitor and non-inhibitor Iranian patients PMID: 29993342
  5. The current study highlights the possible involvement of the IL-2-330T/G Single Nucleotide Polymorphism in susceptibility to B-Cell Non-Hodgkin Lymphoma . Moreover, IL-10-1082A/G is not a molecular susceptibility marker for B-Cell Non-Hodgkin Lymphoma in Egyptians. PMID: 28713071
  6. interleukin-2 (IL-2) is a non-pancreatic autoimmune target in type 1 diabetes PMID: 27708334
  7. The IL-2 AC genotype and C allele of IL-2 (-330A>C) gene polymorphisms could be potential protective factors and might reduce the risk of oral cancer in Indian population. PMID: 29664031
  8. Data show that GIF (ORF117 ) serves as a competitive decoy receptor by leveraging binding hotspots underlying the cognate receptor interactions of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). PMID: 27819269
  9. CD4(+) T cells showed the greatest increase (threefold) in ORMDL3 expression in individuals carrying the asthma-risk alleles, where ORMDL3 negatively regulated interleukin-2 production. The asthma-risk variants rs4065275 and rs12936231 switched CTCF-binding sites in the 17q21 locus. PMID: 27848966
  10. The main mechanism of elimination of mesenchymal stromal cells is cytotoxicity of NK cells that depended on IL-2 production. PMID: 29313232
  11. Uremia patients receiving maintenance hemodialysis with hospitalacquired infection had increased serum inflammatory factors and high throughput hemodialysis significantly decreased CRP, IL2 and TNFalpha levels in the serum, suggesting that high throughput hemodialysis may be beneficial for the prevention of the infections in uremia patients. PMID: 29257244
  12. The simultaneous delivery of multiple proinflammatory payloads to the cancer site conferred protective immunity against subsequent tumor challenges. A fully human homolog of IL2-F8-TNF(mut), which retained selectivity similar to its murine counterpart when tested on human material, may open new clinical applications for the immunotherapy of cancer. PMID: 28716814
  13. Study found that in SLE patients lymphocyte production of IL-2 did not decrease when compared with that of normal subjects. PMID: 29911835
  14. Peripheral blood Tregs failed to effectively utilize IL-2 and had relatively little STAT5 phosphorylation in active ankylosing spondylitis. PMID: 27901054
  15. correction for individual cytokine expression levels revealed qualitative differences of cytokine profiles characterized by significantly increased TNFalpha and decreased IL-2-expressing T-cell proportions in long-term type-1-diabetes patients. PMID: 28377612
  16. CD45 is a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells PMID: 28655861
  17. genetic polymorphism is associated with increased susceptibility to chronic spontaneous urticaria in Iran PMID: 28159384
  18. PLX4032, a selective BRAF-i, has no inhibitory effect either on NK cell proliferation in response to cytokines IL-2 or IL-15 PMID: 27563819
  19. Results suggest that IL-6 and IL-2 were influenced non-specifically by the presence of a mental disorder and by demographic variables of gender, ethnicity and BMI. Implications of these findings are discussed, as well as possible long-term impact of the identified interleukin differences on immunologic, inflammatory, neuropsychiatric and other systems. PMID: 28486207
  20. possible associations between the IL-2 polymorphisms +114 T>G (rs2069763) and -330 T>G (rs2069762) and the development of gastric cancer; these associations were then correlated with the presence of H. pylori; results show that, among patients with H. pylori infection, the -330 GG and +114 TT genotypes are significantly associated with a high risk of developing gastric cancer, as is the -330G/+114T haplotype PMID: 28458166
  21. Overrepresentation of certain alleles, genotypes and haplotypes in IL-2 gene in febrile seizure patients could predispose individuals to this disease PMID: 28843235
  22. Data reported that let-7i upregulates IL-2 expression by targeting the promoter TATA-box region, which functions as a positive regulator. In HIV-1 infection, the expression of let-7i in CD4(+) T cells is decreased by attenuating its promoter activity. The reduced let-7i miRNA expression led to a decline in IL-2 levels which contributes to CD4(+) T cells death. PMID: 27145859
  23. IL-2 and IL-6 work together to enhance influenza-specific CD8 T cell generation responding to live influenza virus in aged mice and humans PMID: 27322555
  24. the aim of the current review article is to determine the roles of IL-2 IL-2/IL-2R interaction in polyoma BK virus reactivation and PBK associated nephropathy complications. PMID: 27718431
  25. Modulation of IL-2, IL-4, IFN-gamma and/or TNF-alpha levels, or inhibitors of Erk1/2 or S6K1 may be a new approach to prevent BAFF-induced aggressive B-cell malignancies. PMID: 27235588
  26. Our results show that the frequency of Tregs is altered in a large cohort of long-term T1D patients, a profound decrease in CD25 expression and altered IL-2 signaling are typical features of Tregs populations in long-term diabetic patients and their relatives. PMID: 27560779
  27. a role for circulating IL-2 in liver dysfunction and propose that a combined assessment of AST/ALT in conjunction with IL-2 at the early stages of symptomatic DENV infection may be useful to predict the severe forms of dengue. PMID: 27155816
  28. Lymphocytes incubated in the presence of IL-2 lose the capacity for chemotaxis but acquire antitumor activity PMID: 28429264
  29. the central biological role of the novel IL-2-R/Lck/PLCgamma/PKCtheta;/alphaPIX/Rac1/PYGM signalling pathway is directly related to the control of fundamental cellular processes such as T cell migration and proliferation. PMID: 27519475
  30. F42K can circumvent the expansion and negative immunoregulatory effects of highly suppressive ICOS+ Tregs, while promoting NK cell expansion and function. F42K also induces a unique gene expression profile and does not activate many IL2-induced genes, although it has the capacity to activate NK cells and NK cell-associated activation genes, costimulatory molecules, and NK-mediated cytolytic function PMID: 27697858
  31. Chimeric fusion protein of interleukin 2 (IL2) and its receptor interleukin 2 receptor, beta protein (IL2Rbeta) enhances antitumor activity of natural killer NK92 cells. PMID: 28916655
  32. Il2 was not a useful discriminative markers for active tuberculosis among pulmonary tuberculosis suspects. PMID: 27450011
  33. IL-2 and IL-10 could work synergistically to improve the survival, proliferation, and cytotoxicity of activated CD8(+) T cells, an effect suppressible by CD4(+)CD25(+) Treg cells PMID: 28274688
  34. results show that IL-23 accounts for the main aspects of human and murine lupus including the expansion of double negative T cells, decreased IL-2, and increased IL-17 production PMID: 28646040
  35. Report efficient retroviral vector transduction of primary human natural killer cells that were stimulated by a combination of IL-2 and engineered K562 cells expressing membrane-bound IL-21 for cancer immunotherapy. PMID: 28802832
  36. upon ligation of the T-cell antigen receptor (TCR), the TCR associates with and transactivates CXCR4 via phosphorylation of S339-CXCR4 in order to activate a PREX1-Rac1-signaling pathway that stabilizes interleukin-2(IL-2), IL-4, and IL-10 messenger RNA (mRNA) transcripts. PMID: 28694325
  37. IL2 induces disruption of adherens junctions, concomitant with cytoskeletal reorganization, ultimately leading to increased endothelial cell permeability. PMID: 27601468
  38. findings extend understanding of the differential modes of action between IL-2 and IL-15, and highlight how, although sharing the CD122/CD132 receptor, they elicit such different immune actions PMID: 28507024
  39. DNA-PKcs is a potent regulator of IL-2 production in T lymphocytes. PMID: 28750002
  40. Yeast-expressed human IL-2 fusion toxin effectively targetedCD25(+) cutaneous T cell lymphoma. PMID: 28551309
  41. study provides evidence that membrane-coated microvesicles released by apoptotic neutrophils suppress a subset of resting Th cells by downregulating IL-2 and IL-2R expression PMID: 28295230
  42. In T1D, low IL-2 responsiveness was most pronounced in memory T effector cells. Reduced IL-2 responses in memory T effector cells were not rescued by resting, remained lower after activation and proliferation, and were absent in type 2 diabetes. PMID: 28645874
  43. the elevated level of IL-2+ and IL-21+ T cells and a positive correlation between IL-21+ cells with clinical activity index in ulcerative colitis patients may contribute to the pathogenesis of disease. PMID: 28685527
  44. analysis of the contribution of IL2Rgamma to the dynamic formation of IL2-IL2R complexes PMID: 27195783
  45. lack of local IL-2 enhances regulatory T-cell susceptibility to Fas-mediated apoptosis induced by epithelial cells PMID: 26928938
  46. The IL-2 rs2069762 G allele appeared to be a protective mutation against aplastic anemia, but no significant differences were found in other four IL-2 and Il-8 SNPs studied. PMID: 28268223
  47. Pristimerin inhibits IL-2 induced T cell activation and generation of lymphokine-activated killer cells by disrupting multiple cell signaling pathways induced by IL-2. PMID: 28471123
  48. IL-2 or induced killer cells combination therapy was efficacious in treating NSCLC and improved overall survival. Further analysis of trials having adequate information and data need to be done to confirm these findings. PMID: 27748271
  49. Treatment of memory CD4 T cells with the concentration of kynurenine found in plasma inhibited IL-2 signaling through the production of reactive oxygen species. PMID: 27356894
  50. Ochratoxin A mediates MAPK activation, modulates IL-2 and TNF-alpha mRNA expression and induces apoptosis by mitochondria-dependent and mitochondria-independent pathways in human CD4 positive T-cell lymphoma cell line. PMID: 27193732

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed